Johnson & Johnson news

   Watch this stock
Showing stories 11 - 20 of about 117   

Articles published

JNJ 105.55 -1.26 (-1.18%)
price chart
Update: FDA Clears Johnson & Johnson's Insulin Pump, An Artificial Pancreas ...
Animas, a Johnson & Johnson unit, has won FDA approval for its Animas Vibe insulin pump. In my original article, I said that Johnson & Johnson's artificial pancreas may be launched much earlier than expected. The FDA clearance of the Animas Vibe ...
Related articles »  
Is Johnson & Johnson Still A Worthy Buy?
Disclaimers: is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.
Johnson & Johnson: JNJ Stock Is Flashing a Bullish Signal
Looking at Johnson & Johnson's price movement since the second half of 2012, we see a stock moving sharply higher along with its sector.
Johnson & Johnson Price Target Increased to $114.00 by Analysts at ...  The Legacy
How Much Do Fair-Value Estimates Help The Retail Investor? (JNJ)  Seeking Alpha
Related articles »  
Kliein ISD nurses attend Johnson & Johnson Leadership program
In July 2013 six nurses from Klein ISD attended the highly competitive Johnson & Johnson School Health Leadership Program in New Brunswick.
Dividend Aristocrats In Focus Part 52 Of 54: Johnson & Johnson (JNJ)
Johnson & Johnson has increased EPS for 30 consecutive years and dividends per share for 52 consecutive years. Johnson & Johnson's stock is less volatile than most utilities. The company is extremely well-diversified and has 4 separate competitive ...
Dividend Aristocrat: Johnson & Johnson (JNJ)
Johnson & Johnson (NYSE:JNJ) is a leading health care company with a diverse revenue base. Johnson & Johnson is also a member of the elite group of stocks called Dividend Aristocrats. To qualify, a company has to be part of the S&P 500 and have ...
Related articles »  
Pharmalot, Pharmalittle: We're Reading About Stryker, Johnson & Johnson and ...
Good morning, everyone, and how are you today? Most likely, you may feel a bit soggy if you are located anywhere near the Pharmalot campus, where much more than a spot of rain is falling.
Johnson & Johnson (JNJ) Strikes $935 Million Deal With Geron Corporation ...
The pharmaceutical giant paid an upfront amount of $35 million for the rights to acquire the company's pipeline product which is, as of now, in early stages of development.
Related articles »  
Novartis (NVS) Beats Johnson & Johnson (JNJ) In Clinical Trial
Novartis AG's (ADR) (NYSE:NVS) plaque psoriasis treatment Cosentyx continued to produce impressive results in its clinical trial.
Novartis AG and Amgen Inc. Take Aim at Johnson & Johnson  Nasdaq
Related articles »  
Johnson & Johnson (JNJ), Bayer (BAYRY) Against Consolidation Of Xarelto ...
Xarelto is jointly owned by Johnson & Johnson and Bayer and as per the terms of agreement between the two companies, Johnson & Johnson has the US rights of the product, whereas Bayer is responsible for the production of the drug and has rights over ...